CORVUS PHARMACEUTICALS INC (CRVS)
US2210151005 - Common Stock
ChartMill assigns a Buy % Consensus number of 84% to CRVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.78. This target is 415.07% above the current price.
CRVS was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CRVS.
In the previous month the buy percentage consensus was at a similar level.
CRVS was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-03-27 | Mizuho | Maintains | Neutral -> Neutral |
| 2024-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-16 | Mizuho | Reiterate | Neutral -> Neutral |
| 2023-05-30 | Ladenburg Thalmann | Maintains | Buy -> Buy |
| 2023-05-09 | Cantor Fitzgerald | Maintains | Overweight |
| 2023-03-30 | Mizuho | Reiterate | Neutral |
| 2022-10-07 | Ladenburg Thalmann | Initiate | Buy |
| 2021-12-03 | Cantor Fitzgerald | Maintains | Overweight |
| 2021-12-01 | Jefferies | Initiate | Buy |
| 2021-08-03 | Mizuho | Maintains | Neutral |
| 2021-07-16 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-27 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-03-26 | HC Wainwright & Co. | Maintains | Buy |
| 2021-02-10 | Mizuho | Downgrade | Buy -> Neutral |